OBJECTIVES: The aim of this study is to compare the total cost of subcutaneous trastuzumab (SC-TRA) vs intravenous trastuzumab (IV-TRA) for HER2+ breast cancer patients from the R. Macedonia. Recent studies suggest that SC-TRA has a pharmacokinetic profile and efficacy non-inferior to standard IV-TRA and is a valid alternative for the treatment of eligible breast cancer patients. METHODS: A cost-minimization analysis was performed using data from prior prospective time-motion study. Total time and cost of both types of TRA administration were quantified in a time horizon of over 18 cycles therapy course.The total of 169 patients (mean weight 74.20 kg) (300 observed episodes) from two oncology clinics were enrolled. Patients were HER2+ and received the drug in the adjuvant (132 patients) or first line metastatic (37 patients) setting. Health care resources included drug treatment, patient’s room and chair time treatments, active healthcare professional time and consumables. Non-health care resources encompassed patients’ transport.  The model accounted the 3%wastage of IV-TRA administration. Unit costs were obtained utilizing official (government and hospital pharmacy) publicly available data and they were expressed in Euro 2015, with no discount. RESULTS: Direct medical costs per (mean weight) patient were €30 500 for IV-TRA and €30 102 for SC-TRA. The mean total costs per patient of IV compared to SC administratuin of TRA over the full course of treatment were €30 695 and €30 106, respectively. SC-TRA incurred less non-drug related cost (€4,20) than IV-TRA (€196). The results of the model were most sensitive to patient weight and % of wastage in IV treated patients. Mean cost saving per patient over a full treatment course for SC administration was €589,2. Mean savings (preparation and administration) in time with SC-TRA were 47 min. CONCLUSIONS: SC-TRA can be time and cost-saving therapy for HER2+ breast cancer patients from the R. Macedonia.